Novo Nordisk Competition -2.3% as GLP-1 Pressure Builds
Can Novo Nordisk Competition derail the obesity leader’s comeback before oral Wegovy and Medicare access have a chance to matter? Maik Kemper Editor in Chief Novo Nordisk A/S’s…
Novo Nordisk Share Repurchase -2.5% Warning for Bulls
Is Novo Nordisk using its buyback to signal confidence, or to steady nerves as competition and cyber risks unsettle investors? Maik Kemper Editor in Chief The buyback is…
Eli Lilly Jaypirca Approval +6.8% as CHMP Backs CLL Use
Can Eli Lilly Jaypirca Approval turn a regulatory win into a lasting oncology growth engine for investors? Maik Kemper Editor in Chief The CHMP’s positive opinion reflects compelling…
Novo Nordisk Share Repurchase Drives a 6.4% Rally
Can Novo Nordisk’s massive buyback and Wegovy pill momentum outweigh a fresh cyber threat and keep this rally alive? Maik Kemper Editor in Chief The Wegovy pill is…
Novo Nordisk Wegovy Faces a Warning in the Obesity Race
Can Novo Nordisk Wegovy regain momentum fast enough to challenge Eli Lilly before the next wave of obesity drugs resets the market? Maik Kemper Editor in Chief Oral…
Eli Lilly Orforglipron Powers $19.8B Surge as Risks Rise
Can Eli Lilly Orforglipron justify Lilly’s trillion-dollar valuation as GLP-1 growth accelerates and pricing pressure starts to bite? Maik Kemper Editor in Chief Eli Lilly Orforglipron’s oral profile,…
Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s sales? Maik Kemper Editor in Chief With the…
Novo Nordisk Wegovy Trial Drives 4.2% Stock Surge
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1 combination wave? Maik Kemper Editor in Chief Combination…
Eli Lilly Zepbound Coverage +5.2% as CVS Restores Access
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war? Maik Kemper Editor in Chief “Collaboration with pharmaceutical companies…
AbbVie MAVIRET Approval Gets EMA Backing for Acute HCV
Could AbbVie’s latest MAVIRET milestone become another quiet growth lever as investors look beyond its biggest blockbuster franchises? Maik Kemper Editor in Chief Conclusion In short, AbbVie MAVIRET…